Brief: Axovant Gene Therapies Announces FDA Clearance Of IND For AXO-AAV-GM2 Gene Therapy In Tay-Sachs And Sandhoff Diseases
09/11/2020 12:13
Nov 9 (Reuters) - Axovant Gene Therapies Ltd AXGT.O :
* AXOVANT GENE THERAPIES ANNOUNCES FDA CLEARANCE OF IND FOR
AXO-AAV-GM2 GENE THERAPY IN TAY-SACHS AND SANDHOFF DISEASES
* AXOVANT GENE THERAPIES - RECEIVED LETTER FROM FDA
INDICATING
THAT CO HAS SATISFACTORILY ADDRESSED ALL ISSUES RELATED TO
CLINICAL HOLD ON AXO-AAV-GM2
Source text for Eikon: ID:nGNXbNkyQ0
Further company coverage: AXGT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sio Gene Therapies
See all newsBrief: Sio Gene Therapies Inc - On March 14, Got Notice That Nasdaq Has Determined That Company's Common Stock Will Be Delisted From Nasdaq Capital Market
Brief: Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results
Brief: Sio Gene Therapies Inc. Announces Board Approval Of Plan Of Complete Liquidation, Dissolution
Brief: Sio Gene Therapies Announces Second Quarter Financial Results
Brief: Sio Gene Therapies Announces Fiscal First Quarter 2022 Financial Results